Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects (J5)
January 26-29, 2026
| Keystone Resort, Keystone, CO, United States
Lora K. Heisler, James Trevaskis, Michael A Cowley and Matthias H. Tschöp
Scholarship Deadline: Sep. 25, 2025 | Abstract Deadline: Jan. 6, 2026 | Early Registration Deadline: Nov. 25, 2025
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Tuesday, January 27, 2026
| 8:00–9:00 AM |
Welcome and Keynote Address (Joint) |
|
| |
Richard D DiMarchi, Indiana University
The Chemical Evolution of Peptides To Transform Human Health |
|
| 9:00–11:15 AM |
Beyond Weight Loss: New Directions for Obesity Therapeutics (Joint) |
|
| |
Rachel J. Roth Flach, Valo Health
Targeting Metabolism for HFpEF |
|
| |
Susan Quaggin, Northwestern University
A United Vision for Kidney and Cardiovascular Disease Treatment |
|
| |
James Trevaskis, Eli Lilly
Incretins for MASH Treatment |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–12:15 PM |
Meet the Editors (Joint) |
|
| |
* Rong Tian, University of Washington
|
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–2:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Emerging Therapies, Lifestyle Interventions and AI Approaches (Joint) |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Late Breaking Research on Obesity Development |
|
| |
Ana Paula Arruda, University of California, Berkeley
Metabolic Adaptations to Nutritional Fluctuations |
|
| |
Jason Gill, University of Glasgow
Ethnic Differences in the Development and Management of Obesity |
|
| |
Randy J. Seeley, University of Michigan
Body Weight Set Point |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 7:30–10:00 PM |
Poster Session 1 |
|
Wednesday, January 28, 2026
| 8:00–11:00 AM |
CNS Mechanisms of Action of Weight Loss |
|
| |
Michael A Cowley, Monash University
Hypothalamic Neurocircuits that Mediate Drug Actions |
|
| |
Lora K. Heisler, Rowett Institute, University of Aberdeen
Brain GPCR Targets and Circuits Controlling Food Intake |
|
| |
Bei B. Zhang, Novo Nordisk
Modulation of GLP-1 and Amylin Receptors for Weight Management |
|
| |
Giuseppe D'Agostino, University of Manchester
Appetite and Body Weight Control via Caudal Brainstem Circuits |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–1:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 1:30–2:45 PM |
Career Roundtable (Joint) |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Leveraging Enteroendocrine Cell Secretion |
|
| |
Shirly Pinto, Kallyope
Unlocking GLP-1 Expressing Cells for Novel Therapeutics |
|
| |
Fiona M. Gribble, University of Cambridge
Mechanisms Underlying Nutrient Sensing in Human Intestinal-Secreting Cells |
|
| |
Kevin G. Murphy, Imperial College London
Dietary Drivers of Gut Hormone Release |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 7:30–10:00 PM |
Poster Session 2 |
|
Thursday, January 29, 2026
| 8:00–11:00 AM |
Emerging Therapies for Obesity and Cardiometabolic Diseases (Joint) |
|
| |
Matthias H. Tschöp, Helmholtz Munich
Dual and Triple Co-Agonists: From Discovery to Best-in-Class |
|
| |
Kirsten Raun, Novo Nordisk A/S
Amylin: The All-Inclusive Obesity Therapeutic |
|
| |
Thomas Alexander Lutz, University of Zürich
Amylin Physiology and its Therapeutic Potential to Treat Metabolic Diseases |
|
| |
Murielle M Véniant-Ellison, Amgen Inc.
Unlocking the Power of GIPR and GLP-1R Targeting for Effective Weight Loss and Metabolic Improvement |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–2:30 PM |
On Own for Lunch |
|
| 1:00–2:00 PM |
Panel: Perspectives: Personalized Medicine & Patient-Centered Strategies (Joint) |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Leveraging Genetics |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Preservation of Muscle Mass and Function during Weight Loss |
|
| |
Mark W. Sleeman, Regeneron Pharmaceuticals
Strategies to Prevent Muscle Loss |
|
| |
Philip Larsen, Sixpeaks Bio AG
Preservation of Skeletal Muscle is a Key to Healthy Weight Loss |
|
| |
Ffolliott M Fisher, Keros Therapeutics
Targeting the TGF-β super Family for the Preservation of Muscle Mass and Weight Loss |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
